Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Core Insights - Autolus Therapeutics plc is set to release its fourth quarter and full year 2024 financial results on March 20, 2025, before the US markets open [1] - A conference call and webcast will be held on the same day at 8:30 am EDT/12:30 pm GMT to discuss the financial results and provide a business update [2] Company Overview - Autolus Therapeutics plc is an early commercial stage biopharmaceutical company focused on developing next-generation T cell therapies for cancer and autoimmune diseases [3] - The company utilizes proprietary T cell programming technologies to create targeted and controlled T cell therapies aimed at effectively recognizing and eliminating target cells [3] - Autolus has an FDA-approved product, AUCATZYL, and is developing a pipeline of candidates for treating hematological malignancies, solid tumors, and autoimmune diseases [3]